Home / Stocks / GILD

Gilead Sciences (GILD, Biotechnology) Stock Valuation & Fair Value Quality business with a solid forward outlook

Gilead Sciences (GILD, Biotechnology) trades at a blended P/E of 53.5, about 254% above its historical normal valuation, with a forward growth estimate of 78.8% and a PEG of 0.68. Analysts' one-year estimates have been hit 64% of the time.

DATA AS OF 2026-08-21
Blended P/E
53.5
Normal P/E
15.1
PEG
0.68
Fwd growth
78.8%
Div yield
2.3%
RSI (14)
63.9
Neutral

Valuation flags

Verdict history

tickerseer's rating moved from high quality, attractively priced for its growth (2026-06-03) to quality business with a solid forward outlook (2026-08-21).

Price and rating by weekClose moved +8.0 percent from 2026-06-03 to 2026-08-17, with 1 rating change over 21 recorded weeks.2026-06-03: High quality, attractively priced for its growth, close 128.15 (recalculated)2026-06-10: High quality, attractively priced for its growth, close 120.69 (recalculated)2026-06-14: High quality, attractively priced for its growth, close 124.77 (recalculated)2026-06-16: High quality, attractively priced for its growth, close 127.23 (recalculated)2026-06-21: High quality, attractively priced for its growth, close 123.76 (recalculated)2026-07-02: High quality, attractively priced for its growth, close 131.27 (recalculated)2026-07-06: High quality, attractively priced for its growth, close 129.61 (recalculated)2026-07-09: High quality, attractively priced for its growth, close 134.84 (recalculated)2026-07-12: High quality, attractively priced for its growth, close 129.83 (recalculated)2026-07-13: High quality, attractively priced for its growth, close 131.40 (recalculated)2026-07-14: High quality, attractively priced for its growth, close 130.04 (recalculated)2026-07-20: High quality, attractively priced for its growth, close 133.21 (recalculated)2026-07-22: High quality, attractively priced for its growth, close 130.34 (recalculated)2026-07-25: High quality, attractively priced for its growth, close 129.31 (recalculated)2026-07-27: High quality, attractively priced for its growth, close 130.52 (recalculated)2026-07-31: High quality, attractively priced for its growth, close 130.21 (recalculated)2026-08-03: High quality, attractively priced for its growth, close 130.212026-08-07: Quality business with a solid forward outlook, close 133.21 (recalculated)2026-08-10: Quality business with a solid forward outlook, close 133.212026-08-14: Quality business with a solid forward outlook, close 138.36 (recalculated)2026-08-17: Quality business with a solid forward outlook, close 138.361281382026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 30.0+99%High quality, attractively priced for its growth
2026-06-10P/E 29.7+97%High quality, attractively priced for its growth
2026-06-14P/E 29.7+97%High quality, attractively priced for its growth
2026-06-16P/E 29.7+97%High quality, attractively priced for its growth
2026-06-21P/E 29.7+97%High quality, attractively priced for its growth
2026-07-02P/E 33.9+125%High quality, attractively priced for its growth
2026-07-06P/E 35.6+136%High quality, attractively priced for its growth
2026-07-09P/E 35.6+136%High quality, attractively priced for its growth
2026-07-12P/E 37.1+146%High quality, attractively priced for its growth
2026-07-13P/E 37.1+146%High quality, attractively priced for its growth
2026-07-14P/E 37.1+146%High quality, attractively priced for its growth
2026-07-20P/E 40.4+168%High quality, attractively priced for its growth
2026-07-22P/E 40.4+168%High quality, attractively priced for its growth
2026-07-25P/E 41.0+172%High quality, attractively priced for its growth
2026-07-27P/E 41.0+172%High quality, attractively priced for its growth
2026-07-31P/E 43.6+189%High quality, attractively priced for its growth
2026-08-03P/E 43.7+189%High quality, attractively priced for its growth
2026-08-07P/E 43.6+189%Quality business with a solid forward outlook
2026-08-10P/E 44.7+196%Quality business with a solid forward outlook
2026-08-14P/E 48.6+222%Quality business with a solid forward outlook
2026-08-17P/E 48.6+222%Quality business with a solid forward outlook
2026-08-21P/E 53.5+254%Quality business with a solid forward outlook ← now

Earnings moves: GILD moved more than the options market implied in 0 of 1 recent tracked reports.

Frequently asked questions

Is Gilead Sciences stock overvalued?

At a blended P/E of 53.5 versus its historical normal P/E of 15.1, Gilead Sciences trades about 254% above its typical valuation, with a PEG of 0.68 on 78.8% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Gilead Sciences's fair value and PEG?

Gilead Sciences trades at a blended P/E of 53.5 against a historical normal P/E of 15.1, a PEG of 0.68, and a forward growth estimate of 78.8%.

Has tickerseer's rating of Gilead Sciences changed?

tickerseer's rating moved from high quality, attractively priced for its growth (2026-06-03) to quality business with a solid forward outlook (2026-08-21).

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track GILD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.